Serina Therapeutics Advances POZ-VMAT2i for Tardive Dyskinesia and Potential Expansion into Huntington's Disease Chorea.

Serina Therapeutics is advancing its novel product candidate, SER-270 (POZ-VMAT2i), for tardive dyskinesia (TD). The once-weekly injectable VMAT2 inhibitor is designed to address adherence, access, and administration barriers in underserved TD patients. Serina also plans to explore development in Huntington's disease chorea, a high need secondary indication.

Huntsville, AL, July 02, 2025 – Serina Therapeutics, Inc. (NYSE American: SER) has announced the advancement of SER-270 (POZ-VMAT2i), a novel once-weekly injectable VMAT2 inhibitor for treating tardive dyskinesia (TD). The drug leverages Serina's proprietary POZ Platform™ technology to provide a long-acting alternative to daily oral medications.

The U.S. TD market, which exceeded $3.7 billion in sales in 2024, is projected to reach $5.4 billion by 2030. Currently, fewer than 30% of U.S. TD patients are diagnosed, with less than half receiving treatment. The company also plans to explore the drug's potential for treating chorea associated with Huntington's disease.

POZ-VMAT2i specifically targets underserved patients who struggle with daily medication adherence, institutionalized patients, and those with dysphagia, offering a potentially transformative solution in the VMAT2 inhibitor market.

Serina Therapeutics aims to address significant unmet needs in the TD market. TD is a disabling and often stigmatizing movement disorder caused by long-term exposure to antipsychotic medications. It predominantly affects those with chronic psychiatric conditions such as schizophrenia and bipolar disorder who may have difficulty adhering to complex daily medication regimens. While oral VMAT2 inhibitors are the only approved class for TD, uptake remains modest due to underdiagnosis, low disease awareness among clinicians, and the challenges of ensuring daily medication adherence in complex, high-risk populations.

Serina's once-weekly injectable POZ-VMAT2i is uniquely positioned to address these barriers. The drug is designed to meet the needs of underserved TD patients who struggle with daily medication adherence, including those already managed with long-acting injectable (LAI) antipsychotics.

In addition to TD, Serina plans to explore the development of POZ-VMAT2i for chorea associated with Huntington's disease, a neurodegenerative disorder marked by progressive movement impairment and often, serious swallowing difficulties. A weekly injectable therapy may offer meaningful advantages over current oral options for this population and their caregivers.

"POZ-VMAT2i embodies Serina’s commitment to solving real-world challenges for patients and caregivers who are often left behind by traditional therapies," said Steve Ledger, Chief Executive Officer of Serina Therapeutics. "By targeting non-compliant, institutionalized, and dysphagic patients with a transformative once-weekly injectable, we believe we can meaningfully expand access to proven VMAT2 inhibitor therapy and improve patient lives."

Serina Therapeutics is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The company's POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs).

References:
[1] https://www.stocktitan.net/news/SER/serina-therapeutics-advances-poz-vmat2i-into-development-for-tardive-0dnj4cldth2l.html